Result of AGM

Evolutec Group PLC
04 May 2005


For immediate release                                                 4 May 2005

                               EVOLUTEC GROUP PLC

                         ('Evolutec' or 'the Company')

                                 Result of AGM



Evolutec Group plc (AIM: EVC), a biopharmaceutical company developing novel
products for the treatment of allergic, inflammatory and autoimmune diseases, is
pleased to announce that all of the resolutions at the AGM of the Company, held
today, were duly passed.



David Bloxham, Evolutec's Chairman, commented: 'The Company is on track with its
plans for the clinical development of rEV131, our lead compound. We are entering
an exciting stage in the development of the Company and expect to deliver two
Phase II clinical trial results by the end of 2005.'











ENDS





For further information:


Evolutec                                                     0118 922 4480
Mark Carnegie Brown, Chief Executive Officer
Nicholas Badman, Chief Financial Officer
www.evolutec.co.uk

Collins Stewart                                              020 7523 8350
Chris Howard

Buchanan Communications                                      020 7466 5000
Mark Court/Tim Anderson/Mary-Jane Johnson





Notes for Editors:



About Evolutec

Evolutec, which is based in Reading, UK, is a clinical stage biopharmaceutical
company with a focus on allergy, inflammation and auto-immune diseases.



 The Company has commenced a 112 patient proof of concept Phase II clinical
trial with rEV131, its lead product, in allergic rhinitis.  Evolutec intends to
carry out additional proof of concept Phase II trials with rEV131 in
post-cataract surgery and dry eye.  Positive pre-clinical data has also been
generated in asthma.  rEV131 is a histamine binding protein and is understood to
be the only product currently in clinical trials that impacts the recently
discovered H4 receptor, a receptor implicated in many forms of inflammatory
disease.



The Company has a further two products in pre-clinical development: rEV598,
which is being evaluated in carcinoid syndrome and CINV (chemotherapy-induced
nausea and vomiting), and rEV576, a complement inhibitor.



Evolutec was founded in 1998 to exploit research carried out by the Natural
Environment Research Council.  Evolutec's drugs were first isolated from the
saliva of ticks. The tick remains undetected by its hosts, including humans, by
injecting an array of molecules into the skin that suppresses normal defence
mechanisms.  These stealth molecules have evolved over millions of years to
enable the tick to take a blood meal from its host. Evolutec employs the tick's
evolutionary stealth technology to offer the potential of treating human
diseases.





Safe Harbour statement: this news release may contain forward-looking statements
that reflect the current expectations of the Company regarding future events.
Forward-looking statements involve risks and uncertainties. Actual events could
differ materially from those projected herein and depend on a number of factors
including the success of the Company's research strategies, the applicability of
the discoveries made therein, the successful and timely completion of clinical
studies, the uncertainties related to the regulatory process, the successful
integration of completed mergers and acquisitions and achievement of expected
synergies from such transactions, and the ability of the Company to identify and
consummate suitable strategic and business combination transactions.




                      This information is provided by RNS
            The company news service from the London Stock Exchange